Our key technologies improve on existing approaches to liquid biopsy for several advantages in cancer detection. PointSuppressor™ (PSP) works seamlessly with any PCR-based assay to suppress unwanted wild type reads, lowering the limit of detection, increasing throughput, and decreasing sequencing costs by orders of magnitude. NexGenAbler™ (NGA) is a highly specific, sensitive, and automation-friendly method for quantitative measurement of mutations in cell-free DNA (cfDNA). MethylMarker™ enables measurement of methylation and mutation detection in the same tube. Each method substantially enhances liquid biopsy. Combined, these technologies will dramatically improve detection and monitoring of cancer.